Medical devices company, TransEnterix (NYSEARCA:TRXC) is another small-cap growth stock that has sprung back to life in 2020. TRXC stock is up a whopping 1322% in the past six months. The company’s robotics platform will likely get significant traction this year, as regulatory approvals will support growth opportunities. The goal is for its “Senhance” robotics technology to gain widespread clinical adoption in the laparoscopic field. A few risks remain, though, and its inflated price limits TRXC stock’s attractiveness. Source: Shutterstock TransEnterix’s Senhance platform essentially reduces variability in surgical procedures and thus improves patient outcomes for laparoscopic procedures. The platform’s initial sales were encouraging but quickly dropped off, as it failed to meet physician expectations. However, the company has worked incredibly hard to fix its teething issues and invested in extensors such as its Intelligent Surgical Unit. FDA
TransEnterix Stock Has Potential, But Wait for a Pullback yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.